While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

Needham hosted an expert to discuss potential impact of trade tariffs and personnel changes on healthcare equities. Generic ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...

Advances recognized by science’s most lucrative awards include Large Hadron Collider experiments and groundbreaking ...

Maxeon Solar Technologies said it is establishing an alternative network of supply-chain partners and increasing its manufacturing capabilities in the U.S. as it deals with new tariffs and trade ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Novo Nordisk has announced major leadership changes, with EVP Camilla Sylvest departing and Ludovic Helfgott taking on an ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...

Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player. Novo Nordisk said it’s ...